EFFICACY OF PSYLLIUM DIETARY FIBERS IN PATIENTS WITH METABOLIC SYNDROME

Abstract

Metabolic syndrome is characterized by increased visceral fat mass, decreased peripheral tissue insulin sensitivity, and hyperinsulinemia, which induce carbohydrate, lipid, and purine metabolic disturbances, an activated systemic inflammatory response, and prothrombogenic shifts in the hemostatic system. Patients with metabolic syndrome have a combination of cardiovascular risk factors, such as arterial hypertension, overweight, and dyslipidemia, which causes us to regard metabolic syndrome as a very high cardiovascular death risk state. The purpose of this study is to make a complex evaluation of the efficiency of long-term use of psyllium (Mucofalk, Dr. Falk Pharma, Germany) in patients with metabolic syndrome during combination therapy. Sixty patients with metabolic syndrome were examined. Thirty patients received standard therapy and 30 patients took psyllium. Addition of psyllium to therapy could bring about an additional weight loss. Blood glucose levels were found to be reduced. During psyllium therapy, there was a decrease in the level of blood fibrinogen and C-peptide. Incorporation of psyllium dietary fibers into combination therapy could provide an additional fall in plasma lipid level in the treatment of patients with metabolic syndrome. At the same time psyllium showed a positive effect in losing weight, regulating eating behavior, relieving the symptoms of intestinal dyspepsia, and recovering the rate of defecation and the levels of fasting glycemia and lipid profile in patients with metabolic syndrome just at 3 months of treatment. The drug exhibits good tolerability and long-term safety.

Keywords

metabolic syndrome / dietary fibers / psyllium

References

[1] Ардатская М. Д. Клиническое значение КЖК при патологии желудочно-кишечного тракта: Автореф. дис.. д-ра мед. наук. — М., 2003.

[2] Ардатская М. Д. Клиническое применение пищевых волокон: Метод. пособие. — М., 2011.

[3] Бышевский А. Ш., Терсенов О. А. Биохимия для врача. — Екатеринбург: Уральский рабочий, 1994.

[4] Готтшалк Г. Метаболизм бактерий: Пер. с англ. — М.: Мир, 1982.

[5] Пат. на изобретение № 2260184 РФ от 2005 года / Минушкин О. Н., Ардатская М. Д. и др. Способ оценки метаболизма желчных кислот и холестерина.

[6] Рекомендации Всероссийского Общества Кардиологов по диагностике и лечению метаболического синдрома // Кардиоваскул. тер. и профилактика. — 2009. — Т. 8, № 6. — Прилож. 2.

[7] Anderson J. W., Bridges S. R. // Proc. Soc. Exp. Biol. Med. — 1984. — Vol. 177. — P. 372—376.

[8] Anderson J. W., Allgood L. D., Turner J. et al. // Am. J. Clin. Nutr. — 1999. — Vol. 70, N 4. — P. 466—473.

[9] Anderson J. W., AllgoodL. D. et al. // Am. J. Clin. Nutr. — 2000. — Vol. 71, N 2. — P. 472—479.

[10] Drucker D. J. // Diabetes. — 1998. — Vol. 47. — P. 159—169.

[11] ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. — 2011. — Vol. 32, N 14. — P. 1769— 1818.

[12] Jenkins D. J., Wolever T. M., Leeds A. R. et al. // Br. Med. J. — 1978. — Vol. 1. — P. 1392—1394.

[13] King D. E., Egan B. M., Woolson R. F. et al. // Arch. Intern. Med. — 2007. — Vol. 167, N 5. — P. 502—506.

[14] Ma Y., Griffith J. A., Chasan-Taber L. et al. // Am. J. Clin. Nutr. — 2006. — Vol. 83, N 4. — P. 760—766.

[15] Mariett J. A., Kajs T. M., Fisher M. H. // Am. J. Clin. Nutr. — 2000. — Vol. 72, N 3. — P. 784—789.

[16] Moreyra Abel E., Wilson Alan C., Koraym Ashraf // Arch. Intern. Med. — 2005. — Vol. 165. — P. 1161—1166.

[17] National Cholesterol Education Program (NCEP). Third Report of the NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart Lung and Blood Institute. — 2002.

[18] Ritzel R., Orskov C., Holst J. J., Nauck M. A. // Diabetologia. — 1995. — Vol. 38. — P. 720—725.

[19] Rodriguez-Moran M., Guerrero-Romero F., Lazcano-Burciaga G. // J. Diabet. Complicat. — 1998. — Vol. 12, N 5. — P. 273—278.

[20] Schirra J., Katschinski M., Weidmann C. et al. // J. Clin. Invest. — 1996. — Vol. 97. — P. 92—103.

[21] Sierra M., Garcia J. J., Fernandez N. et al. // Eur. J. Clin. Nutr. — 2002. — Vol. 56, N 9. — P. 830—842.

[22] Stoffer D. A., Kieffer T. J., Hussain M. A. et al. // Diabetes. — 2000. — Vol. 49. — P. 741—748.

[23] Stewart. // Mol. Nutr. Food Res. — 2000. — Vol. 50, N 10. — P. 971—976.

[24] Thorburn A., Muir J., Proietto J. // Metabolism. — 1993. — Vol. 42. — P. 780—785.

[25] Wang Z. Q., Zuberi A. R., Zhang X. H. et al. // Metabolism. — 2007. — Vol. 56, № 12. — P. 1635—1642.

[26] Wei Z. H., Wang H., Chen X. Y. et al. // Eur. J. Clin. Nutr. — 2009. — Vol. 63, № 7. — P. 821—827.

[27] Weir G. C., Mojsov S., Hendrick G. K., Habener J. F // Diabetes. — 1989. — Vol. 38. — P. 338—342.

[28] Ziai S.A., Larijani B., Akhoondzadeh S. et al. // J. Ethnopharmacol. — 2005. — Vol. 102. — P. 202—207.

RIGHTS & PERMISSIONS

Eco-Vector